Phase 2 trial in 518 participants with painful knee osteoarthritis: monthly IV LEVI-04 at 0.3, 1.0 and 2.0 mg/kg improved WOMAC pain at week 17 vs placebo (LS mean differences -0.51, -0.62, -0.79; all p<0.05), without more serious adverse events.
RCTn = 518
Conaghan et al. Efficacy and safety of LEVI-04 in patients with osteoarthritis of the knee: a randomised, double-blind, placebo-controlled, phase 2 trial